Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The double threat: bacterial and fungal co-/superinfection in viral pneumonia.

Expert review of respiratory medicine·2026

Same author

Machine Learning-Based Identification of Risk Factors for ICU Mortality in 8902 Critically Ill Patients with Pandemic Viral Infection.

Journal of clinical medicine·2025

Same author

Does Empirical Antibiotic Use Improve Outcomes in Ventilated Patients with Pandemic Viral Infection? A Multicentre Retrospective Study.

Antibiotics (Basel, Switzerland)·2025

Same author

Outcomes and predictors of mortality in patients with severe COVID-19 and COPD admitted to ICU: A multicenter study.

Anaesthesia, critical care & pain medicine·2025

Same author

Surveillance of device-associated infection rates at adult intensive care units in the VINCat program (2010-2022).

Enfermedades infecciosas y microbiologia clinica (English ed.)·2025

Same author

Early bacterial co-infections and ventilator-associated lower respiratory tract infections among intubated patients during the first and second COVID-19 waves: a European comparative cohort study.

Respiratory research·2025

Search research articles

Related Experiment Video

Updated: May 10, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Nosocomial pneumonia].

Emili Díaz¹, Ignacio Martín-Loeches, Jordi Vallés

¹Servicio de Medicina Intensiva, Hospital de Sabadell, Corporació Sanitària Universitària Parc Taulí, CIBER Enfermedades Respiratorias, Sabadell, Barcelona, España.

Enfermedades Infecciosas Y Microbiologia Clinica

|July 6, 2013

Summary

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) increase mortality and costs. Identifying common pathogens and resistance patterns is crucial for effective antibiotic therapy and patient outcomes.

Keywords:

Hospital-acquired pneumonia Infección nosocomial Neumonía asociada a ventilación mecánica Neumonía nosocomial Nosocomial infection Ventilator-associated pneumonia

More Related Videos

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Related Experiment Videos

Last Updated: May 10, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Area of Science:

Infectious Diseases
Critical Care Medicine
Hospital Epidemiology

Context:

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are significant nosocomial infections.
These infections are particularly prevalent in patients with acute respiratory failure.
HAP and VAP contribute to increased patient mortality and substantial healthcare costs.

Purpose:

To highlight the critical need for understanding local microbial epidemiology and antimicrobial susceptibility patterns for HAP and VAP.
To emphasize the importance of this knowledge in guiding appropriate empirical antibiotic therapy.
To advocate for the implementation of targeted prevention strategies for HAP and VAP.

Summary:

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent common and serious hospital-acquired infections.
The increasing prevalence of antibiotic-resistant bacteria in HAP necessitates accurate identification of causative organisms and their resistance profiles.
Knowledge of local pathogens and susceptibility is vital to reduce inappropriate antibiotic use and improve patient prognosis.

Impact:

Informed antibiotic selection can decrease treatment failures and mortality rates associated with HAP and VAP.
Effective prevention strategies can reduce the incidence of these costly infections.
Optimizing empirical antibiotic therapy contributes to antimicrobial stewardship and combats resistance.